Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin.

Lee CK, Choi JS, Bang JS.

Korean J Physiol Pharmacol. 2013 Jun;17(3):245-51. doi: 10.4196/kjpp.2013.17.3.245. Epub 2013 Jun 11.

3.

Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.

Li C, Choi DH, Choi JS.

J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):99-108. doi: 10.1007/s10928-011-9234-0. Epub 2012 Jan 1.

PMID:
22210483
4.

Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.

Lee CK, Choi JS, Choi DH.

Pharmacol Rep. 2015 Feb;67(1):44-51. doi: 10.1016/j.pharep.2014.08.005. Epub 2014 Aug 23.

PMID:
25560574
7.

Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.

Choi JS, Piao YJ, Kang KW.

Arch Pharm Res. 2011 Apr;34(4):607-13. doi: 10.1007/s12272-011-0411-x. Epub 2011 May 5.

PMID:
21544726
8.
9.
10.

Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.

Choi SJ, Shin SC, Choi JS.

Arch Pharm Res. 2011 Feb;34(2):309-15. doi: 10.1007/s12272-011-0217-x. Epub 2011 Mar 6.

PMID:
21380815
11.

Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats.

Choi JS, Choi I, Choi DH.

Eur J Drug Metab Pharmacokinet. 2016 Jun;41(3):231-8. doi: 10.1007/s13318-014-0249-y. Epub 2014 Dec 31.

PMID:
25549928
13.

Cyclosporine markedly raises the plasma concentrations of repaglinide.

Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2005 Oct;78(4):388-99.

PMID:
16198658
14.
15.

Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A.

Choi JS, Choi JS, Choi DH.

Biopharm Drug Dispos. 2014 Oct;35(7):382-90. doi: 10.1002/bdd.1905. Epub 2014 Sep 8.

PMID:
24903704
16.
18.

Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.

Li C, Lim SC, Kim J, Choi JS.

Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):175-82. doi: 10.1007/s13318-011-0036-y. Epub 2011 Mar 27.

PMID:
21442417
19.

Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.

Kajosaari LI, Niemi M, Backman JT, Neuvonen PJ.

Clin Pharmacol Ther. 2006 Mar;79(3):231-42. Epub 2006 Feb 7.

PMID:
16513447

Supplemental Content

Support Center